Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer?

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Eric AssenatJean Marc Pascussi

Abstract

In the last few years, several studies have provided a causal link between constitutive activation of nuclear factor kappa-B (NF-kappaB) and the initiation and development of cancer. More recently, it appears that a cancer-induced inflammatory response may be an important factor in the inter-individual variability of the response to and toxic effects of cancer chemotherapy, as well as in the alteration of drug metabolism enzyme expression in patients. The relationships between chronic inflammation (or infection), cancer and drug metabolism are many: chronic infections lead to inflammation, inflammation may lead to cancer, cancer usually leads to an inflammatory syndrome, and inflammation alters the expression of drug metabolising enzymes and thus of the efficiency of cancer chemotherapy. This review focuses on the functional consequences of NF-kappaB activation during oncogenesis and on the expression of the major cytochrome P450s (CYP) involved in anticancer therapies. Finally, the potential role of NF-kappaB as the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer is discussed.

References

Nov 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J V CastellP C Heinrich
Sep 1, 1985·Biochemical Pharmacology·S C DograR R Sharma
Aug 12, 1994·Science·E Kopp, S Ghosh
May 15, 1994·International Journal of Radiation Oncology, Biology, Physics·P A PhilipJ Carmichael
Dec 1, 1995·British Journal of Clinical Pharmacology·K T KivistöM Eichelbaum
Apr 10, 1997·The New England Journal of Medicine·P J Barnes, M Karin
Jun 13, 1997·The Journal of Biological Chemistry·G Zhou, M T Kuo
Jan 9, 1998·Drug Metabolism Reviews·E T Morgan
Apr 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·C S SeitzP A Khavari
May 23, 1998·Annual Review of Immunology·S GhoshE B Kopp
Feb 11, 1999·The New England Journal of Medicine·C Gabay, I Kushner
Jan 29, 2000·Alimentary Pharmacology & Therapeutics·J EadenJ Mayberry
Jun 3, 2000·Annual Review of Immunology·M Karin, Y Ben-Neriah
Mar 7, 2001·Lancet·F Balkwill, A Mantovani
Jul 13, 2001·Pulmonary Pharmacology & Therapeutics·I M Adcock
Aug 21, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·P PérezJ L Jorcano
Oct 27, 2001·British Journal of Clinical Pharmacology·J A Goldstein
Jan 29, 2002·International Immunopharmacology·Christopher B ManningBrooke T Mossman
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Giovanni MantovaniBernhard Elsener
Feb 28, 2002·Frontiers in Bioscience : a Journal and Virtual Library·Karl Münger
Mar 5, 2002·Nature Immunology·Michael Karin, Anning Lin
Mar 20, 2002·Nature Reviews. Cancer·R A Gupta, R N Dubois
Apr 9, 2002·Current Oncology Reports·Fade Aziz Mahmoud, Nilo I Rivera
May 2, 2002·Cell·Sankar Ghosh, Michael Karin
May 11, 2002·Nature Reviews. Cancer·Michael KarinZhi-Wei Li

❮ Previous
Next ❯

Citations

Oct 22, 2008·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Reza ParsanejadDavid J Doolittle
Apr 3, 2012·Biological & Pharmaceutical Bulletin·Nozomu MoriyaFumihiko Kugawa
Feb 14, 2008·Expert Opinion on Therapeutic Targets·Yong-Song GuanPing Li
Aug 9, 2007·International Journal of Cancer. Journal International Du Cancer·Peter E M Gibbs, Mahin D Maines
Nov 16, 2012·PloS One·Tanusree SenMohammad Obaidul Hoque
Jul 8, 2016·Archives of Pharmacal Research·Hyesol Lim, Aree Moon
Mar 25, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jessica K RiegerUlrich M Zanger
Dec 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeroen T M Buters
May 4, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Devendra Kumar, Neerja Trivedi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
L Iyer, M J Ratain
Expert Opinion on Drug Metabolism & Toxicology
Neill James Liptrott, Andrew Owen
European Journal of Clinical Pharmacology
Nuntiya SomparnVeerapol Kukongviriyapan
Oral Oncology
Xabier Marichalar-MendiaJose M Aguirre-Urizar
© 2021 Meta ULC. All rights reserved